Kiniksa Pharmaceuticals (KNSA)
Markets ARCALYST for recurrent pericarditis while advancing a cardiovascular-focused clinical pipeline.
Something off on this page? Send us feedback.
Markets ARCALYST in the United States for recurrent pericarditis while developing a cardiovascular-focused clinical pipeline. Its business is built around a sole commercial product and its own specialty salesforce.
ARCALYST is Kiniksa’s only commercial product, marketed in the United States for recurrent pericarditis through its own specialty salesforce. The cardiovascular-focused biopharmaceutical company also retains a clinical pipeline. It focuses on therapies for patients with unmet medical need and cardiovascular indications.
The business initially developed from worldwide rights to rilonacept and commercialized the therapy after FDA approval in 2021. Its operations are concentrated in the United States, where nearly all full-time employees work.
Kiniksa was redomiciled from Bermuda to the United Kingdom, with the former Bermuda parent liquidated in 2025.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 30, 2026 | Goldman Sachs | Reiterate | Rating: —Target: $75 | Target: $90 |
| Jul 29, 2026 | Wedbush | Reiterate | Rating: —Target: $72 | Target: $99 |
| Jul 29, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $62 | Target: $98 |
| Jul 23, 2026 | Goldman Sachs | Reiterate | Rating: —Target: $55 | Target: $75 |
| Jul 13, 2026 | Wells Fargo | Reiterate | Rating: —Target: $34 | Target: $74 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $525.9M · Total debt $8.9M · Total assets $896.1M · Shareholders' equity $654.1M
- Revenue
- $243.6M
- Operating income
- $27.2M
- Net income
- $25.4M
No dividends on record.
| Institutions | ≈ 149.84% | 233.82M shares | |
|---|---|---|---|
| 276 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.76% | 1.18M shares | |
| 12 holders · as of Sep 3, 2026 | |||
| Adds to | 150.60% | ||
156.05M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (156.05M in the company's Sep 23, 2026 report, 76.21M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 150.60%; nothing is left for Other.
This company has 5 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 22.34% | 6.97M A · 6.97M A · 6.97M A · 6.97M A · 6.97M A | as of Jun 30, 2026 |
Rubric Capital Management LPInstitution | 12.82% | 4.00M A · 4.00M A · 4.00M A · 4.00M A · 4.00M A | as of Jun 30, 2026 |
Baker Bros. Advisors LPInstitution | 9.08% | 2.83M A · 2.83M A · 2.83M A · 2.83M A · 2.83M A | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.78% | 2.74M A · 2.74M A · 2.74M A · 2.74M A · 2.74M A | as of Jun 30, 2026 |
Tang Capital Management LLCInstitution | 7.24% | 2.26M A · 2.26M A · 2.26M A · 2.26M A · 2.26M A | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 3, 2026 | Michael R. Megna | officer: CHIEF ACCOUNTING OFFICER | −4,600 | $80.30 |
| Jul 29, 2026 | G. Bradley Cole | director | −3,673 | $81.43 |
| May 1, 2026 | John F. Paolini | officer: CHIEF MEDICAL OFFICER | −58,424 | $53.71 |
| May 1, 2026 | Sanj K. Patel | director, officer: CHAIRMAN & CEO | −48,565 | $54.02 |
| Apr 30, 2026 | Sanj K. Patel | director, officer: CHAIRMAN & CEO | −2,141 | $54.01 |
- Cardiol Therapeutics
Late-stage oral therapy in recurrent pericarditis
- Eli Lilly
Owner of a Phase 2 oral NLRP3 program in recurrent pericarditis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals | $75.96 | −2.61% | $5.94B | 79.6 | 47.3 | 7.1 | +55.4% |
| Cardiol Therapeutics | $1.83 | −3.17% | $217.9M | — | — | — | — |
| Eli Lilly | $1,154.59 | −1.33% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Median | 39.3 | 28.2 | 13.8 | +47.7% |